Volume 21, Issue 3 (2018)                   mjms 2018, 21(3): 147-152 | Back to browse issues page

XML Persian Abstract Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Ameri Z, Mehmannavaz Y. Relationship of 536C/T Tissue Factor Pathway Inhibitor Gene and Alu_I/D Tissue-type Plasminogen Activator Gene Polymorphisms with Recurrent Pregnancy Loss in Iranian Azeri Women. mjms 2018; 21 (3) :147-152
URL: http://mjms.modares.ac.ir/article-30-16183-en.html
Relationship of 536C/T Tissue Factor Pathway Inhibitor Gene and Alu_I/D Tissue-type Plasminogen Activator Gene Polymorphisms with Recurrent Pregnancy Loss in Iranian Azeri Women
Z. Ameri1 , Y. Mehmannavaz 2
1- Biology Department, Biological Sciences Faculty, Ahar Branch, Islamic Azad University, Ahar, Iran
2- Biology Department, Biological Sciences Faculty, Maragheh Branch, Islamic Azad University, Maragheh, Iran , mehman10@iau-maragheh.ac.ir
Abstract:   (8645 Views)
Aims: Tissue factor pathway inhibitor (TFPI) and tissue plasminogen activator (tPA) deficiency would cause an increase in the viscosity of fibrinogen and low digestion of blood clot, respectively, which are among the dangerous factors responsible for the increase in thrombosis. Although there are reports, indicating the relationship of vein thrombosis and recurrent pregnancy loss (RPL), the effect of polymorphisms connected with thrombosis on the risk of increasing RPL has remained unclear. Thus, the aim of this study was to evaluate the relationship of 536C/T tissue factor pathway inhibitor gene and Alu_I/D tissue-type plasminogen activator gene polymorphisms with recurrent pregnancy loss in Iranian Azeri women.
Materials and Methods: The present case-control study was conducted in Azari women with RPL and healthy women during 2015-2016. Ninety-five women with RPL were selected by simple random sampling sampling method, and 95 healthy women were selected and assessed, using Multiplex ARMS-PCR method. The data were analyzed by SAS 9.2 software, using logistic regression and Chi-square test.
Findings: Among two genes polymorphisms, only tPA polymorphism was significantly related with the increase in RPL, such that allele I in this polymorphism caused more than two-folded odds ratio of RPL compared to allele D. Women between the ages of 25 and 35 years significantly showed the highest odds ratio of RPL.
Conclusion: Alu_I/D tissue-type plasminogen activator gene polymorphism is related with an increased risk of RPL in Azeri women in northwestern Iran, but 536C/T tissue factor pathway inhibitor gene does not show such a relationship.
Keywords: Abortion Habitual, Thrombosis, Tissue factor pathway inhibitor, Tissue plasminogen activator, Genetic Polymorphism
Full-Text [PDF 659 kb]   (2354 Downloads)    
Article Type: Original Manuscipt | Subject: Biochemistry
Received: 2018/01/29 | Accepted: 2018/04/16
References
1. Rull K, Nagirnaja L, Laan M. Genetics of recurrent miscarriage: Challenges, current knowledge, future directions. Front Genet. 2012;3:34. [Link] [DOI:10.3389/fgene.2012.00034]
2. Amodio G, Canti V, Maggio L, Rosa S, Castiglioni MT, Rovere-Querini P, et al. Association of genetic variants in the 3' UTR of HLA-G with Recurrent Pregnancy Loss. Hum Immunol. 2016;77(10):886-91. [Link] [DOI:10.1016/j.humimm.2016.06.020]
3. Lyons P. Obstetrics in family medicine: A practical guide. 2nd Edition. New York City: Humana Press; 2015. pp. 91-4. _11 [Link] [DOI:10.1007/978-3-319-20077-4]
4. Wolf CE, Haubelt H, Pauer HU, Hinney B, Krome-Cesar C, Legler TJ, et al. Recurrent pregnancy loss and its relation to FV Leiden, FII G20210A and polymorphisms of plasminogen activator and plasminogen activator inhibitor. Pathophysiol Haemost Thromb. 2003;33(3):134-7. [Link] [DOI:10.1159/000077821]
5. Abu-Heija A. Thrombophilia and recurrent pregnancy loss: Is heparin still the drug of choice?. Sultan Qaboos Univ Med J. 2014;14(1):e26-36. [Link] [DOI:10.12816/0003333]
6. Khan S, Dickerman JD. Hereditary thrombophilia. Thromb J. 2006;4:15. [Link] [DOI:10.1186/1477-9560-4-15]
7. Guerra-Shinohara EM, Bertinato JF, Tosin Bueno C, Cordeiro Da Silva K, Burlacchini De Carvalho MH, Pulcineli Vieira Francisco R, et al. Polymorphisms in antithrombin and in tissue factor pathway inhibitor genes are associated with recurrent pregnancy loss. Thromb Haemost. 2012;108(4):693-700. [Link]
8. Crawley JT, Lane DA. The haemostatic role of tissue factor pathway inhibitor. Arterioscler Thromb Vasc Biol. 2008;28(2):233-42. [Link] [DOI:10.1161/ATVBAHA.107.141606]
9. Skretting G, Stavik B, Landvik NE, Myklebust CF, Iversen N, Zienolddiny S, et al. Functional characterization of polymorphisms in the human TFPI gene. Biochem Biophys Res Commun. 2010;397(1):106-11. [Link] [DOI:10.1016/j.bbrc.2010.05.078]
10. González-Conejero R, Lozano ML, Corral J, Martínez C, Vicente V. The TFPI 536C→ T ‎mutation is not associated with increased risk for venous or arterial thrombosis. Thromb Haemost. 2000;83(5):787-8. [Link] [DOI:10.1055/s-0037-1613911]
11. Kamal K, Amit S, Kanwaljeet S, Ravi R, Hareram P, Ravi K, et al. Association of genetic polymorphisms with plasma TFPI level: Boon or curse for DVT patients - study from India. Blood Cells Mol Dis. 2017;66:31-6. [Link] [DOI:10.1016/j.bcmd.2017.08.003]
12. Ludwig M, Wohn KD, Schleuning WD, Olek K. Allelic dimorphism in the human tissue-type plasminogen activator (TPA) gene as a result of an Alu insertion/deletion event. Hum Genet. 1992;88(4):388-92. [Link] [DOI:10.1007/BF00215671]
13. Brandt JT. Plasminogen and tissue-type plasminogen activator deficiency as risk factors for thromboembolic disease. Arch Pathol Lab Med. 2002;126(11):1376-81. [Link]
14. Van Zonneveld AJ, Veerman H, Macdonald ME, Van Mourik JA, Pannekoek H. Structure and function of human tissue-type plasminogen activator (t-PA). J Cell Biochem. 1986;32(3):169-78. [Link] [DOI:10.1002/jcb.240320302]
15. Oguzulgen IK, Ekim N, Erkekol FO, Altinok B, Akar N. Is tissue-plasminogen activator gene polymorphism a risk factor for venous thromboembolism in every population?. J Thromb Thrombolysis. 2005;19(1):61-3. [Link] [DOI:10.1007/s11239-005-0941-5]
16. Hooper WC, Lally C, Austin H, Renshaw M, Dilley A, Wenger NK, et al. The role of the t-PA I/D and PAI-1 4G/5G polymorphisms in African-American adults with a diagnosis of myocardial infarction or venous thromboembolism. Thromb Res. 2000;99(3):223-30. [Link] [DOI:10.1016/S0049-3848(00)00236-X]
17. Poursadegh Zonouzi A, Chaparzadeh N, Ghorbian S, Sadaghiani MM, Farzadi L, Ghasemzadeh A, et al. Theassociation between thrombophilic gene mutations and recurrent pregnancy loss. J Assist Reprod Genet. 2013;30(10):1353-9. [Link] [DOI:10.1007/s10815-013-0071-5]
18. Torabi R, Zarei S, Zeraati H, Zarnani AH, Akhondi MM, Hadavi R, et al. Combination of thrombophilic gene polymorphisms as a cause of increased the risk of recurrent pregnancy loss. J Reprod Infertil. 2012;13(2):89-94. [Link]
19. Lwaleed BA, Bass PS. Tissue factor pathway inhibitor: Structure, biology and involvement in disease. J Pathol. 2006;208(3):327-39. [Link] [DOI:10.1002/path.1871]
20. Hooper WC, El-Jamil M, Dilley A, Philipp C, Ellingsen D, Phillips D, et al. The relationship between the tissue plasminogen activator Alu I/D polymorphism and venous thromboembolism during pregnancy. Thromb Res. 2001;102(1):33-7. [Link] [DOI:10.1016/S0049-3848(01)00220-1]
Send email to the article author

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.